机构:[1]Capital Med Univ, Sch Gen Practice & Continuing Educ, Beijing, Peoples R China;[2]Capital Med Univ, Beijing TianTan Hosp, Dept Gen Practice, Beijing, Peoples R China;首都医科大学附属天坛医院[3]Capital Med Univ, Beijing TianTan Hosp, Dept Neurol, Vasc Neurol, Beijing, Peoples R China;重点科室诊疗科室神经病学中心神经病学中心首都医科大学附属天坛医院[4]Capital Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Beijing, Peoples R China;[5]Capital Med Univ, Beijing TianTan Hosp, Dept Neurol, Tiantan Clin Trial & Res Ctr Stroke, Beijing, Peoples R China重点科室诊疗科室神经病学中心神经病学中心首都医科大学附属天坛医院
Objective: We recently measured the longitudinal use of secondary prevention medication following hospital discharge and the factors influencing persistence in patients with acute ischemic stroke (AIS) and transient ischemic attack (TIA) in China. Methods: Patients with AIS and TIA who were enrolled in the China National Stroke Registry II from June 2012 to January 2013 were surveyed to determine persistence. The medications included antiplatelet therapies, warfarin, antihypertensive therapies, statins, and diabetes medications. We determined persistence for a three-month period following discharge. Persistence was defined as the continuation of all secondary preventive medications prescribed upon hospital discharge. The factors associated with medication persistence 3 months after discharge were examined using a multivariable logistic regression. Results: Of the 21,592 patients with AIS and TIA, 18,344 (91.2%) were eligible for analysis. After 3 months post-discharge, 46.2% of the subjects continued to take all secondary prevention medications prescribed at discharge. Independent predictors of three-month medication persistence included younger age, absence of a history of diabetes or atrial fibrillation, higher family income, less severe stroke, index cerebrovascular event of ischemic stroke, and being treated in a hospital with a stroke unit and more beds in the neurology department. Conclusions: More than half of patients with AIS and TIA reported discontinuing one or more secondary prevention medications within 3 months of hospital discharge. Several factors associated with medication persistence were identified. Here, we propose strategies that could be implemented to improve the quality of secondary prevention.
基金:
Ministry of Science and Technology of the People's Republic of ChinaMinistry of Science and Technology, China [2011BAI08B02, 2012ZX09303, 2013BAI09B03]; Beijing Municipal Committee of Science and Technology [Z161100000516223]; Beijing Institute for Brain Disorders [BIBD-PXM2013_014226_07_000084]; program for New Century Excellent Talents in UniversityProgram for New Century Excellent Talents in University (NCET) [NCET-13-0917]
第一作者机构:[1]Capital Med Univ, Sch Gen Practice & Continuing Educ, Beijing, Peoples R China;[2]Capital Med Univ, Beijing TianTan Hosp, Dept Gen Practice, Beijing, Peoples R China;
通讯作者:
通讯机构:[1]Capital Med Univ, Sch Gen Practice & Continuing Educ, Beijing, Peoples R China;
推荐引用方式(GB/T 7714):
Jiang Yue,Yang Xiaomeng,Li Zixiao,et al.Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China[J].NEUROLOGICAL RESEARCH.2017,39(6):492-497.doi:10.1080/01616412.2017.1312792.
APA:
Jiang, Yue,Yang, Xiaomeng,Li, Zixiao,Pan, Yuesong,Wang, Yilong...&Wang, Chen.(2017).Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China.NEUROLOGICAL RESEARCH,39,(6)
MLA:
Jiang, Yue,et al."Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China".NEUROLOGICAL RESEARCH 39..6(2017):492-497